MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report
MiNK Therapeutics (NASDAQ: INKT), a clinical-stage biopharmaceutical company focused on developing innovative invariant natural killer T (iNKT) cell therapies, has scheduled its second quarter 2025 financial results announcement for August 14, 2025, before market opening.
The company will host a conference call and webcast at 8:30 a.m. ET to discuss the quarterly results and provide a corporate update. Investors can access the call through dial-in numbers for New York (646-307-1963) and USA/Canada (800-715-9871) using Conference ID 1149380, or via webcast on the company's investor relations website.
MiNK Therapeutics (NASDAQ: INKT), una società biofarmaceutica in fase clinica focalizzata sullo sviluppo di innovative terapie con cellule iNKT (invariant natural killer T), ha programmato l'annuncio dei risultati finanziari del secondo trimestre 2025 per il 14 agosto 2025, prima dell'apertura del mercato.
La società terrà una conference call e una webcast alle 8:30 a.m. ET per discutere i risultati trimestrali e fornire un aggiornamento aziendale. Gli investitori potranno partecipare alla chiamata tramite i numeri di accesso per New York (646-307-1963) e USA/Canada (800-715-9871) utilizzando il Conference ID 1149380, oppure via webcast sul sito web delle relazioni con gli investitori della società.
MiNK Therapeutics (NASDAQ: INKT), una empresa biofarmacéutica en fase clínica enfocada en desarrollar innovadoras terapias con células iNKT (células T natural killer invariantes), ha programado el anuncio de sus resultados financieros del segundo trimestre de 2025 para el 14 de agosto de 2025, antes de la apertura del mercado.
La compañía realizará una llamada conferencia y una transmisión en vivo a las 8:30 a.m. ET para discutir los resultados trimestrales y proporcionar una actualización corporativa. Los inversores podrán acceder a la llamada mediante los números de marcación para Nueva York (646-307-1963) y EE.UU./Canadá (800-715-9871) usando el ID de conferencia 1149380, o a través de la transmisión en vivo en el sitio web de relaciones con inversores de la empresa.
MiNK Therapeutics (NASDAQ: INKT)는 혁신적인 불변 자연살해 T세포(iNKT) 치료제 개발에 주력하는 임상 단계 바이오제약 회사로서, 2025년 2분기 재무 실적 발표를 2025년 8월 14일 시장 개장 전으로 예정했습니다.
회사는 분기 실적 및 회사 업데이트를 논의하기 위해 동부 표준시 오전 8시 30분에 컨퍼런스 콜 및 웹캐스트를 진행할 예정입니다. 투자자들은 뉴욕 전화번호(646-307-1963) 및 미국/캐나다 전화번호(800-715-9871)를 통해 컨퍼런스 ID 1149380으로 전화 접속하거나 회사 투자자 관계 웹사이트에서 웹캐스트를 통해 참여할 수 있습니다.
MiNK Therapeutics (NASDAQ : INKT), une société biopharmaceutique en phase clinique spécialisée dans le développement de thérapies innovantes à base de cellules T naturelles tueuses invariantes (iNKT), a programmé l'annonce de ses résultats financiers du deuxième trimestre 2025 pour le 14 août 2025, avant l'ouverture des marchés.
La société organisera une conférence téléphonique et une webdiffusion à 8h30 heure de l'Est pour discuter des résultats trimestriels et fournir une mise à jour d'entreprise. Les investisseurs pourront accéder à l'appel via les numéros d'appel pour New York (646-307-1963) et USA/Canada (800-715-9871) en utilisant l'ID de conférence 1149380, ou via la webdiffusion sur le site des relations investisseurs de la société.
MiNK Therapeutics (NASDAQ: INKT), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung innovativer invarianter natürlicher Killer-T-Zelltherapien (iNKT) spezialisiert hat, hat die Bekanntgabe der Finanzergebnisse für das zweite Quartal 2025 für den 14. August 2025 vor Börsenöffnung geplant.
Das Unternehmen wird um 8:30 Uhr ET eine Telefonkonferenz und einen Webcast abhalten, um die Quartalsergebnisse zu besprechen und ein Unternehmensupdate zu geben. Investoren können über die Einwahlnummern für New York (646-307-1963) und USA/Kanada (800-715-9871) mit der Konferenz-ID 1149380 teilnehmen oder den Webcast auf der Investor-Relations-Website des Unternehmens verfolgen.
- None.
- None.
NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its second quarter 2025 financial results before the market opens on Thursday, August 14, 2025. MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update.
Conference Call
Dial-in numbers: 646-307-1963 (New York), 800-715-9871 (USA & Canada)
Conference ID: 1149380
Webcast
A live webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company’s website at:
https://investor.minktherapeutics.com/events-and-presentations and via https://edge.media-server.com/mmc/p/qjwyn82w
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels.
Forward Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These forward-looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of the most recent Form 10-K, Form 10-Q and the S-1 Registration Statement filed with the SEC. MiNK cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and MiNK undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Investor Contact
917-362-1370
Media Contact
communications@minktherapeutics.com
Source: MiNK Therapeutics
FAQ
When will MiNK Therapeutics (INKT) report Q2 2025 earnings?
How can investors access MiNK Therapeutics' Q2 2025 earnings call?
What type of cell therapies is MiNK Therapeutics developing?
What time is MiNK Therapeutics' Q2 2025 earnings call?
